HAE
Haemonetics Corporation
NYSE: HAE · HEALTHCARE · MEDICAL DEVICES
$120.28
+0.12% today
Updated 2026-11-03
Market cap
$5.38B
P/E ratio
57.16
P/S ratio
3.98x
EPS (TTM)
$2.07
Dividend yield
—
52W range
$49 – $124
Volume
0.7M
Haemonetics Corporation (HAE) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$120.28
12-Month target
$56.83
2030 Target
—
Intrinsic (DCF)
$87.57
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.2B | $1.3B | $1.4B | $1.3B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 7.12%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.